Need professional-grade analysis? Visit stockanalysis.com
$34.50B
N/A
317
N/A
InSilico Medicine Cayman TopCo (3696) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Technology sector under the Software - Infrastructure industry. The stock currently trades at HKD68.35, up 12.42% from the previous close.
Over the past year, 3696 has traded between a low of HKD29.98 and a high of HKD76.85. The stock has gained 128.0% over this period. It is currently 11.1% below its 52-week high.
InSilico Medicine Cayman TopCo has a market capitalization of $34.50B.
InSilico Medicine Cayman TopCo operates as an artificial intelligence (AI)-based biotech company that helps to develop and manufacture novel drugs in Hong Kong, the United States, the United Kingdom, Mainland China, and internationally. The company develops solutions to discover and develop drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. It also offers Pharma.AI platform, a commercially end-to-end generative Al software and automation platform which is designed to enhance the quality and productivity of pharmaceutical research. The company has a strategic partnership with Liquid AI for the development of lightweight AI foundation models for drug discovery; and has a strategic research collaboration with ASKA Pharmaceutical Co., Ltd. to identify novel therapeutic targets with high drug development potential for challenging gynecological conditions, including endometriosis, uterine fibroids, and adenomyosis. The company was founded in 2014 and is based in New Territories, Hong Kong.
Side-by-side comparison against top Technology peers.